Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias.
A North American registry for rare bleeding disorders [factor (F)II, factor (F)VII, factor (F)X, factor (F)V, factor (F)XIII, fibrinogen deficiencies and dysfibrinogenemias] was established to gather information about disease prevalence, genotyping frequency, diagnostic events, clinical manifestations, treatment and prophylaxis strategies, as well as disease- and treatment-related complications. Questionnaires were sent to 225 hemophilia treatment centers in the USA and Canada. Among 26% of responding centers, 294 individuals [4.4% of the registered children (200/4583) and 2.4% of adults (94/3809)] were diagnosed with one or more of the rare bleeding disorders (RBDs) included in this survey. The ethnic distribution for each disorder paralleled that of the general US population with the exception of the disproportionately large number of Latinos with FII deficiency. Only 5.4% of affected individuals were genotyped. An abnormal preoperative bleeding screen most often led to diagnosis. The most common coagulopathy was FVII deficiency; however, 40% of homozygous patients were asymptomatic. FX and FXIII deficiencies caused the most severe bleeding manifestations. Among all RBDs, the most common sites of bleeding were skin and mucus membranes. Multiple products were used to treat hemorrhage; however, half of the bleeding episodes required no therapy. The majority of patients suffered no long-term complications from hemorrhage. Treatment-related complications included viral seroconversion, anemia, allergic reactions and venous access device-related events. This registry provides the most comprehensive information to date about North American individuals with RBDs and could serve as an important resource for both basic scientist and clinician.
Acharya
S S
SS
Division of Hematology-Oncology, Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA. dmdimich@med.cornell.edu
Coughlin
A
A
Dimichele
D M
DM
D000293:Adolescent; D000328:Adult; D000347:Afibrinogenemia / Q000453:epidemiology / Q000235:genetics; D000368:Aged; D001779:Blood Coagulation Factors / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D020147:Coagulation Protein Disorders / Q000453:epidemiology* / Q000235:genetics / Q000628:therapy; D005166:Factor V Deficiency / Q000453:epidemiology / Q000235:genetics; D005168:Factor VII Deficiency / Q000453:epidemiology / Q000235:genetics; D005171:Factor X Deficiency / Q000453:epidemiology / Q000235:genetics; D005177:Factor XIII Deficiency / Q000453:epidemiology / Q000235:genetics; D015241:Fibrinogens, Abnormal; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007020:Hypoprothrombinemias / Q000453:epidemiology / Q000235:genetics; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D012042:Registries; D012189:Retrospective Studies
D001779:Blood Coagulation Factors; D015241:Fibrinogens, Abnormal